Your browser doesn't support javascript.
loading
Safety of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease.
Alsadik, Shahad; Gnanasegaran, Gopinath; Chen, Luohai; Mandair, Dalvinder; Toumpanakis, Christos; Caplin, Martyn; Navalkissoor, Shaunak.
Afiliação
  • Alsadik S; Neuroendocrine Unit, Royal Free London NHS Foundation Trust, London, United Kingdom; s.navalkissoor@nhs.net s.alsadik@nhs.net.
  • Gnanasegaran G; Department of Nuclear Medicine, Royal Free London NHS Foundation Trust, London, United Kingdom.
  • Chen L; Department of Gastroenterology, Royal Free London NHS Foundation Trust, London, United Kingdom; and.
  • Mandair D; First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Toumpanakis C; Neuroendocrine Unit, Royal Free London NHS Foundation Trust, London, United Kingdom.
  • Caplin M; Neuroendocrine Unit, Royal Free London NHS Foundation Trust, London, United Kingdom.
  • Navalkissoor S; Neuroendocrine Unit, Royal Free London NHS Foundation Trust, London, United Kingdom.
J Nucl Med ; 63(10): 1503-1508, 2022 10.
Article em En | MEDLINE | ID: mdl-35210299
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tumores Neuroendócrinos / Insuficiência Renal Crônica Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tumores Neuroendócrinos / Insuficiência Renal Crônica Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article